<DOC>
	<DOC>NCT01530048</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to test if there is bioequivalence between the insulin aspart 100 U/mL (U100) formulation and the new insulin aspart 200 U/mL (U200) formulation.</brief_summary>
	<brief_title>Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)</brief_title>
	<detailed_description />
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Considered to be healthy as judged from vital signs, medical history, ECG (electrocardiogram), laboratory values, and physical examination Body mass index between 18 and 27 kg/m^2 (both inclusive) Nonsmoker Fasting blood glucose maximum 6 mmol/L HbA1c below 6.4% Pregnant or breastfeeding women Women not using acceptable methods of contraception without difficulties for at least three months prior to trial start (screening), including intrauterine devices, oral contraceptives, hormonal implants, or sterilisation Clinically significant abnormal laboratory values (as judged by the Investigator) Close relative with type 1 diabetes mellitus (father, mother, sister or brother) Intake of alcohol within the last 24 hours prior to screening and drug administration visits Blood donation or blood loss of more than 500 mL within the 3 last months before screening Strenuous exercise within 48 hours before screening as well as drug administration and followup Smoking during the past month before drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>